Treatment options and prognosis for HER2 (human epidermal growth factor receptor 2)-positive breast cancer has improved over the last decade with the availability of advanced HER2-targeted treatments and antibody–drug conjugates. This evidence concerns the gene ERBB2 and breast cancer.